
Opinion|Videos|June 9, 2025
The importance of studying efficacy and safety of treatment in Black patients with mHSPC
Author(s)Quoc-Dien Trinh, MD, MPH
Research highlights the need for personalized treatment in mHSPC, addressing variations in drug efficacy across diverse populations for optimal patient care.
Advertisement
Episodes in this series

Importance of Personalized Medicine
Key Themes:
- Drug efficacy and safety may vary across different subpopulations.
- Considerations extend beyond race to other demographic factors.
- There is a potential need for personalized dosing approaches.
- Targeted studies are crucial for clinician confidence and patient reassurance.
Key Points for Physicians:
- Consider individual characteristics beyond race when selecting treatments.
- Recognize the growing importance of personalized medicine approaches.
- Communicate clearly with patients about evidence supporting treatment recommendations.
Notable Insights: The discussion of personalized medicine extends beyond race to consider the broader landscape of individual variation in drug response and tolerability.
Clinical Significance: Advancing personalized medicine approaches, including subgroup-specific analyses, will improve cancer care by appropriately tailoring treatments to individual and population characteristics.
Advertisement
Related to this article

Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.

The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.

Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.

John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.

Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
Advertisement
Advertisement
Trending on Urology Times
1
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
2
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
3
Aglatimagene besadenovec shows sustained immune remodeling in localized prostate cancer
4
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
5



